New Rhein Healthcare Investors
Akhil Akula currently serves as Vice President at New Rhein Healthcare Investors, a life sciences venture capital and growth equity firm, since June 2022. Akhil holds several board positions including Member of the Board of Directors at American Injectables and Clickspring Design, and serves as a Board Observer for Neuraptive Therapeutics, Inc. Previously, Akhil worked in Corporate Development at Pfizer, contributing to M&A and partnership execution while initiating Pfizer's Breakthrough Growth Initiatives. Other professional experiences include roles at HealthCare Royalty Partners, MTS Health Partners, Ziegler, Grant Thornton LLP, and Deutsche Bank. Akhil earned a Bachelor's Degree in Business Administration with a focus on Finance and Pre-Med from the University of Richmond's Robins School of Business.
This person is not in any teams
This person is not in any offices
New Rhein Healthcare Investors
New Rhein is a Venture Capital/ Private Equity investor. Its partners are former pharmaceutical industry executives having both operational and M&A experience. New Rhein invests in healthcare companies with the objective of helping management teams build their business into a profile strategic investors would find attractive. We use our knowledge of what strategic buyers want and our relationships to help our portfolio companies achieve this goal. Investment areas of focus include specialty Rx (eg hospital), branded and difficult to make Gx, OTC, biologics, vaccines, and emerging markets (in particular China and Brazil). We are interested in product only deals, carve-outs and entire company purchases.